Intra-Cellular Therapies
ITCI
$66.84
Share price
1.72%
Change (1 day)
2.97%
Change (1 year)
Categories
Revenue for Intra-Cellular Therapies (ITCI)
Revenue in 2023 (TTM): $0.46 B
According to Intra-Cellular Therapies's latest financial reports the company's current revenue (TTM
) is $0.46 B.
In 2022 the company made a revenue of $0.24 B an increase over the years 2021 revenue that were of $81.7 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Intra-Cellular Therapies from 2014 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | $0.46 B | 85.51% |
| 2022 | $0.24 B | 204.91% |
| 2021 | $81.7 M | 262.65% |
| 2020 | $22.53 M | 37071.49% |
| 2019 | $0.06 M | |
| 2018 | N/A | |
| 2017 | N/A | |
| 2016 | N/A | -100% |
| 2015 | $0.03 M | -94.4% |
| 2014 | $0.54 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Xencor XNCR | $0.16 B | -63.58% | 🇺🇸 USA |
 MediciNova MNOV | $1 M | -99.78% | 🇺🇸 USA |
 Curis CRIS | $10.02 M | -97.83% | 🇺🇸 USA |